TARA - NASDAQ

Protara Therapeutics, Inc.

Protara Therapeutics, Inc.

TARAยทNASDAQ

$4.22

-1.2%
HealthcareBiotechnology

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$162.85M
EPS-1.3400
P/E Ratio-3.15
Earnings Date07/30/2026
Protara Therapeutics, Inc.

Protara Therapeutics, Inc. Fair Value Envelope

TARA ยท NASDAQ

Our analysis suggests that TARA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.22, this represents a potential HIDDEN relative to our calculated worth for Protara Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $4.22

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$48.6M
+ Cash & Equivalents$49.7M
Firm Value$1.1M
- Debt$3.4M
Equity Value-$2.3M
/ Shares Outstanding38,581,863B
DCF Value-$0
OVERVALUED BY 101%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$28.2M
-$14.1M
-$7.0M
-$3.5M
-$1.8M
-$880.7K
-$440.4K
-$220.2K
-$110.1K
-$55.0K
Maintenance CapEx
-$9.4K
-$4.7K
-$2.4K
-$1.2K
-$588
-$294
-$147
-$73
-$37
-$18
Owner Earnings
-$28.2M
-$14.1M
-$7.0M
-$3.5M
-$1.8M
-$881.0K
-$440.5K
-$220.2K
-$110.1K
-$55.1K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$26.1M
-$12.1M
-$5.6M
-$2.6M
-$1.2M
-$555.2K
-$257.0K
-$119.0K
-$55.1K
-$25.5K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your TARA research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.